Case Report: Palopegteriparatide as a novel therapeutic option in pediatric autosomal dominant hypocalcemia type 1

1

Autosomal dominant hypocalcemia type 1 (ADH1) is caused by gain-of-function variants in the CASR gene, leading to hypocalcemia and related complications.
2

A 16-year-old boy with ADH1 experienced severe symptoms despite standard therapy, including hypocalcemia, seizures, and nephrocalcinosis.
3

Palopegteriparatide was initiated off-label due to inadequate control with conventional treatments, resulting in improved biochemical stability.
4

The patient achieved complete resolution of tetany and was able to discontinue alfacalcidol and calcium supplementation after treatment.
5

This case suggests that palopegteriparatide may be a promising option for pediatric ADH1 patients when standard therapies fail.

Frontiers In Endocrinology

by Arkadiusz Zygmunt, Anna Fedorczak, Łukasz Krotowski, Anna Łupińska, Kinga Sałacińska, Agnieszka Gach, Michael Mannstadt, Renata Stawerska
June 17, 2026

1